Back to Results
First PageMeta Content
GlaxoSmithKline / Pharmacology / Fluticasone/salmeterol / Chronic lower respiratory diseases / Salmeterol / Asthma / Fluticasone propionate / Bronchodilator / Placebo / Medicine / Pulmonology / Respiratory therapy


IMPORTANT REVISIONS TO PRESCRIBING INFORMATION FOR SEREVENT® (salmeterol xinafoate) AND ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) GlaxoSmithKline PO Box 13398
Add to Reading List

Open Document

File Size: 40,29 KB

Share Result on Facebook

Company

GlaxoSmithKline / M.D. / /

Country

United States / /

/

MedicalCondition

prescribed asthma / COPD / acutely deteriorating asthma / usual asthma / asthma / /

MedicalTreatment

mechanical ventilation / /

Organization

Food and Drug Administration / /

Person

Kathleen A. Rickard / Respiratory / /

/

Position

physician / Vice President / /

Product

fluticasone propionate / ADVAIR DISKUS / albuterol / SEREVENT / /

URL

www.FDA.gov/medwatch / www.gsk.com / /

SocialTag